Celon Pharma S.A. (WSE:CLN)

Celon Pharma Statistics

Total Valuation

Celon Pharma has a market cap or net worth of PLN 1.20 billion. The enterprise value is 1.18 billion.

Market Cap	1.20B
Enterprise Value	1.18B

Important Dates

The last earnings date was Wednesday, September 17, 2025.

Earnings Date	Sep 17, 2025
Ex-Dividend Date	n/a

Share Statistics

Celon Pharma has 53.86 million shares outstanding. The number of shares has increased by 2.47% in one year.

Current Share Class	38.86M
Shares Outstanding	53.86M
Shares Change (YoY)	+2.47%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	20.32%
Float	23.82M

Valuation Ratios

PE Ratio	n/a
Forward PE	130.67
PS Ratio	5.79
PB Ratio	3.10
P/TBV Ratio	3.13
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-17.08
EV / Sales	5.70
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-22.02

Financial Position

The company has a current ratio of 1.78, with a Debt / Equity ratio of 0.05.

Current Ratio	1.78
Quick Ratio	1.32
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	-0.37
Interest Coverage	-29.40

Financial Efficiency

Return on equity (ROE) is -16.31% and return on invested capital (ROIC) is -9.04%.

Return on Equity (ROE)	-16.31%
Return on Assets (ROA)	-7.51%
Return on Invested Capital (ROIC)	-9.04%
Return on Capital Employed (ROCE)	-15.33%
Revenue Per Employee	363,914
Profits Per Employee	-121,485
Employee Count	558
Asset Turnover	0.39
Inventory Turnover	2.70

Taxes

In the past 12 months, Celon Pharma has paid 3.09 million in taxes.

Income Tax	3.09M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.42% in the last 52 weeks. The beta is 0.84, so Celon Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.84
52-Week Price Change	-25.42%
50-Day Moving Average	22.98
200-Day Moving Average	24.15
Relative Strength Index (RSI)	42.91
Average Volume (20 Days)	10,147

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Celon Pharma had revenue of PLN 206.34 million and -68.88 million in losses. Loss per share was -1.30.

Revenue	206.34M
Gross Profit	133.92M
Operating Income	-63.60M
Pretax Income	-65.80M
Net Income	-68.88M
EBITDA	-22.88M
EBIT	-63.60M
Loss Per Share	-1.30

Balance Sheet

The company has 38.98 million in cash and 19.88 million in debt, giving a net cash position of 19.10 million or 0.35 per share.

Cash & Cash Equivalents	38.98M
Total Debt	19.88M
Net Cash	19.10M
Net Cash Per Share	0.35
Equity (Book Value)	385.11M
Book Value Per Share	7.25
Working Capital	53.14M

Cash Flow

In the last 12 months, operating cash flow was -9.38 million and capital expenditures -44.06 million, giving a free cash flow of -53.44 million.

Operating Cash Flow	-9.38M
Capital Expenditures	-44.06M
Free Cash Flow	-53.44M
FCF Per Share	-0.99

Margins

Gross margin is 64.90%, with operating and profit margins of -30.82% and -33.38%.

Gross Margin	64.90%
Operating Margin	-30.82%
Pretax Margin	-31.89%
Profit Margin	-33.38%
EBITDA Margin	-11.09%
EBIT Margin	-30.82%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.08, which amounts to a dividend yield of 0.36%.

Dividend Per Share	0.08
Dividend Yield	0.36%
Dividend Growth (YoY)	-11.11%
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.47%
Shareholder Yield	-2.10%
Earnings Yield	-5.76%
FCF Yield	-4.47%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2